 ESC guidelines. (Cardiol J 2018; 25, 4: 512-520) 
Introduction
Heart failure (HF) is a clinical syndrome with many different underlying etiologies such as coronary artery disease, hypertension, myocarditis, valvular heart disease, arrhythmias, alcoholism, lysosomal storage diseases or amyloidosis [1] [2] [3] [4] [5] .
Despite the fact that there have been substantial improvements in the management of HF in recent years, HF continues to encounter problems with high mortality, morbidity and an increasing rate of recurrent hospitalizations due to decompensated chronic HF [1, [6] [7] [8] [9] . Therefore, currently a key issue is to optimize outpatient treatment of HF. The role of ambulatory treatment and follow-up provided by general practitioners and outpatient cardiac clinics cannot be underestimated in an effective rapid response to first signs of decompensation and in optimization of pharmacotherapy to slow down HF progression.
Thanks to clinical trials including patients with ischemic and hypertensive etiology of HF, we have implemented European Society of Cardiology (ESC) guidelines helpful in managing patients with HF according to the evidence based medicine. However, in contrary to well-established treatment of patients with ischemic and hypertensive origin of HF, there is a lack of clinical trials on other HF etiologies, and accordingly their management appears to be less clear [1] .
The aim of this study was to investigate the Polish population of outpatients with systolic HF and to compare the clinical profile and applied treatment in patients with non-ischemic, nonhypertensive HF versus patients with ischemic or hypertensive etiology of HF.
Methods

Study population and protocol
A prospective multicenter DATA-HELP (DiAgnotic and TherApeutic methods used in patients with systolic HEart Failure Living in Poland) study was performed between October and December 2009 in Poland. Stratified randomization was conducted by Cegedim Strategic Data among all general practitioners (GPs) and cardiologists working in outpatient clinics with the algorithm based on the generation of pseudorandom numbers according to Wichman and Hill [10] . A random sample of physicians (500 cardiologists and 290 GPs) were invited to complete a questionnaire regarding the clinical status, medical history, administered diagnostic tests, applied therapy, recent hospitalizations and outpatient visits in 10 consecutive patients with systolic HF. Physicians were instructed to recruit patients with stable systolic HF and made responsible for the complex management of their treatment.
Recruited patients had to fulfil the following inclusion criteria: -age ≥ 18 years; -clinical diagnosis of HF based on current European recommendations; -left ventricular ejection fraction (LVEF) ≤ 45%; -outpatient visit from October to December 2009. This investigation conformed with the principles outlined in the Declaration of Helsinki. The study protocol was registered and approved by all involved ethics committees.
Detailed clinical data about information obtained from the questionnaires were completed by cardiologists and general practitioners about their outpatients with stable systolic HF are contained in the paper 'Comparison of clinical profile and management of outpatients with HF with reduced LVEF treated by general practitioners and cardiologist in contemporary Poland: the results from the DATA-HELP registry' Jankowska et al. (paragraph 2.2. Information obtained) [11] . Additionally, information about the number and kind of hospitalizations (urgent vs. planned; in cardiac vs. in other departments) and outpatient visits (in internal medicine vs. cardiac clinics vs. general practitioner practice vs. other specialized outpatient clinics) within 12 months preceding the study was obtained.
Studied groups
All outpatients with stable systolic HF recruited into the DATA-HELP registry were divided into three groups according to the etiology of HF: -patients with non-ischemic, non-hypertensive etiology (study group, in which the background of hypertensive and ischemic heart disease was excluded by their GP/cardiologist); -patients with ischemic etiology (with coronary artery disease as a major underlying etiology of HF, with previous myocardial infarction and/ or after revascularization -percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]); -patients with arterial hypertension without concomitant coronary artery disease.
Statistical analyses
Continuous variables were expressed as mean ± standard deviations when they were normally distributed or medians with lower and upper quartiles for variables with a skewed distribution. The categorized variables were presented as numbers with percentages. The statistical significance of differences between the groups were tested using analysis of variance (Kruskal-Wallice test), Student's t-test, or the c 2 test, where appropriate. A value of p < 0.05 was considered statistically significant.
Statistical analyses were performed using STATISTICA 10 data analysis software system (StatSoft, Inc).
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Results
5563 outpatients with systolic HF were enrolled in the study -59% data (3300 patients) came from outpatient cardiology practices and 34% (1895 patients) from GPs. 10% (546) of patients had etiologies other than ischemic and hypertensive, whereas in 76% of patients coronary artery disease was the leading cause of HF (Fig. 1) . Both in men and women, the prevalence of non-ischemic and non-hypertensive HF decreased with the increasing age. Among younger patients (< 50 years old) every second patient with systolic HF had neither hypertensive nor ischemic heart disease (Figs. 2, 3) .
In the non-ischemic and non-hypertensive groups there were patients with a shorter duration of the disease than in the ischemic group (Table 1) . Patients in non-ischemic and non-hypertensive group were characterized by younger age and fewer co-morbidities (diabetes mellitus type 2, previous stroke/transient ischemic attack, chronic obstructive pulmonary disease/asthma). In this group patients experienced more advanced HF, here defined as more severe symptoms of HF classified as New York Heart Association (NYHA) class III or IV, on physical examination (pulmonary congestion, hepatomegaly, jugular vein distension, third heart sounds) and LVEF < 20% (Table 1) .
Patients with non-ischemic and non-hypertensive HF received beta-blockers less frequently and angiotensin converting enzyme inhibitor/ /angiotensin receptor blocker (ACEI/ARB) with lower target doses. In contrast, they received more frequent mineralocorticoid receptor antagonists (MRA), but without differences in target doses of MRA between studied groups. Patients with nonischemic and non-hypertensive HF more often needed symptomatic treatment with loop diuretics and digoxin and had cardiac resynchronization therapy (CRT) and implanted cardioverter-defibrillator (ICD) implanted in contrast to patients from other groups ( Table 2) .
Evaluation of patients' past medical history revealed that in the group of patients with nonischemic and non-hypertensive etiology of HF Figure 3 . The prevalence of non-ischemic and non--hypertensive etiology of heart failure according to age and gender of patients with stable systolic heart failure (n = 5563). there were more cardiac hospitalizations (both urgent and planned) than in hypertensive group, however there was no significant difference when compared with the ischemic group. There were differences in all non-cardiac hospitalizations and the total number of hospital admissions. Patients with non-ischemic and non-hypertensive HF were less often seen in outpatient clinics than other groups (Table 3) .
Discussion
The major finding of this study revealed HF of non-ischemic and non-hypertensive origin www.cardiologyjournal.org predominantly affects young adults, who despite suffering from more advanced HF than patients with ischemic or hypertensive etiology of HF, are not optimally managed, possibly due to the lack of clinical trials and evidence based guidelines on how to treat patients with non-ischemic and nonhypertensive HF.
Jankowska et al. [11] based on the same DATA--HELP registry has elegantly described some observed differences between the clinical profile and management of outpatients with HF supervised by GPs versus those treated by cardiologists. They observed that patients treated by GPs were older, had more comorbidities, less commonly received beta-blocker and MRA, less often had implantable devices (ICD and CRT) and underwent coronary revascularization. Therefore, these findings should also be taken into consideration, as they may play a role in optimization and improvement in management of outpatients with HF.
Ischemic heart disease (defined as a history of myocardial infarction, revascularization by PCI and/or CABG or coronary artery disease confirmed in coronarography), either alone (28%) or together Table 2 . Comparison of treatment in systolic heart failure between three studied groups of patients: with non-ischemic and non-hypertensive etiology, with hypertensive and non-ischemic etiology, and with ischemic etiology.
Parameters
Treatment of patients with systolic heart failure (n = 5563) with hypertension (72%), is the most common cause of HF and is present in three-fourths of outpatients with chronic HF. It is noteworthy here to mention the study from McMurray et al. [2] , in which they raised difficulties with clear adjustment of primary etiology of HF in patients with multiple potential causes (especially with coexisting ischemic heart disease and hypertension). Hypertension, without concomitant diagnosis of ischemic heart disease, was the second most common cause of HF. In comparison with the Rywik et al. study [12] noteing the prevalence of coexisting ischemic and hypertensive etiology of HF which has remained at a similar level in Poland for more than 10 years (55% in the present study vs. 53%), while ischemic heart disease alone appears less often to be a primary cause of HF than in the previous decade (21% vs. 26%). Nowadays hypertension as a primary cause of HF is more common (14% vs. 8%), whereas non-ischemic and non-hypertensive etiology of HF has slightly decreased currently (10% vs. 12%) [12] .
In the studied registry, non-ischemic and nonhypertensive etiology of HF was found in every tenth outpatient with systolic HF and this prevalence increased up to 46% in patients below 50 years of age.
Among patients with non-ischemic and nonhypertensive HF there are patients suffering from cardiac arrhythmias, valve dysfunction, cardiomyopathy (dilated, alcoholic, toxic, idiopathic etc.), pericardial disease (i.e. constrictive pericarditis) or past infections (viral myocarditis, rheumatic fever, HIV, Chagas disease) [2, 3, 13] . Unfortunately, the diagnostic process to discover etiology of HF often only results in eliminating some of the possible causes i.e. ischemic, hypertensive and arrhythmic and valve dysfunction. Thus, many patients are labelled as 'non-ischemic and non-hypertensive' HF, without finding the underlying cause of HF and as a consequence, it could be difficult, if not www.cardiologyjournal.org impossible to treat them effectively. Taking into account possible causes of HF in the group of patients with non-ischemic and non-hypertensive HF in this study it was found that 45% of patients had a history of atrial fibrillation (more than in ischemic group -31%, p < 0.0001, but similar to hypertensive group -48%), 27% had valve dysfunction (more than in the ischemic group -10%, p < 0.001, but less than in the hypertensive group -33%, p < 0.05; however there is an important limitation in the interpretation of this data from the registry -there was no information about location and severity of valve dysfunction), 35% had possible post-infectious etiology (more than in ischemic -1% and hypertensive group -12%, all p < 0.001) and 10% were alcoholics (again more than in ischemic -2.5% and hypertensive group -3%, all p < 0.001). After exclusions of the aforementioned diagnosed and potential causes of HF in 108 patients (2% of all studied patients with HF and 20% of patients classified primary as non-ischemic and non-hypertensive etiology), no possible etiology has been found and can be classified as idiopathic HF. Especially in this population of patients with HF, it appears to be justified to perform more sophisticated investigations like cardiac magnetic resonance or even heart biopsy, however it must be pointed out, that these kinds of examinations should take place only in clinics with experience in performing and describing results of these procedures [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
It appeared that only suggestions about diagnosis were obtained, without clear guidelines how treat patients with non-ischemic and nonhypertensive cause of HF.
The registry revealed that patients with nonischemic and non-hypertensive etiology were treated sub-optimally according to the latest ESC guidelines on treatment of HF with reduced LVEF [1] . Not only did fewer patients from this group receive ACEI/ARB (90%), but they also rarely achieved the target dose of those medications (only 20% of patients). Patients with non-ischemic and non-hypertensive HF were more frequently treated with MRA (70%). There was however, no difference in achieving the target dose of MRA between the studied groups. Despite a great improvement in treatment and outcomes in patients with HF over the last two decades [25] , there are still many problems in reaching the target doses of recommended medications in ambulatory practice dispite this issue having been widely discussed in the literature [26, 27] . In the group of patients with non-ischemic and non-hypertensive etiology reported more hospitalizations in cardiac departments than in the hypertensive group and fewer outpatient visits.
It was observed that despite substantial percentage of patients having indications for implantation of CRT/ICD device only 9% finally had such a device implanted. Of note, patients with nonischemic and non-hypertensive HF received ICD/ /CRT therapy twice as often than the two other group. Van Veldhuisen et al. [28] on the basis of the EUROMED Registry pointed out that implantable devices are underutilised in CHF patients with major differences across various countries (with the highest rate of ICD implants in Germany and the lowest rate was in Spain; data from Poland was not obtained). In the ESC-HF Pilot Survey performed in 12 European countries during the same time frame as the present study -from October 2009 to May 2010 -only 23% of patients with chronic HF had ICD/CRT implanted [29] . Also, in the recent PARADIGM-HF trial, despite careful selection of optimally managed patients, again 22% received CRT/ICD therapy [30] .
Limitation of the study
An important limitation of this study, as in all registries performed on large populations in multicenter settings, is that it is linked with a questionnaire type study and has limited opportunities for data verification. It must be emphasized, that this study relied entirely on the judgement of physicians regarding the underlying etiology of HF in their patients. Therefore, as in all studies based on questionnaires, assumptions were taken that all data would be provided reliably according to the rules of Good Clinical Practice, including the selection of patients to be recruited for the registry as well as the reporting of all data.
Despite the aforementioned limitations, there is also a great advantage of these type of studies. They reflect a real-world clinical practice which can be confronted with the applicable guidelines, thus answering an important question: how do physicians treat ten consecutive patients with HF for whom they are fully responsible?
During the study design 7900 outpatients were expected to be included in the registry (by 500 cardiologists and 290 GPs), but completed data was obtained in just 5563 of those patients. Nevertheless, the big sample size allowed treating this population as representative of Polish outpatients with stable systolic heart failure.
